Samantha N. Serna

Samantha N. Serna

Auto-generated profile, based on publicly available information

Samantha N. Serna

Department of Pharmacology and Toxicology, Center for Human Toxicology, University of Utah, Salt Lake City, Utah

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2025 in Molecular Pharmacology
Verified
Journal Article
Open access
LSLili Sun
Lili Sun
JLJohn G. Lamb
John G. Lamb
Changshan NiuChangshan Niu
Changshan Niu
SSSamantha N. Serna
Samantha N. Serna
ERErin Gail Romero
Erin Gail Romero
CRChristopher A. Reilly
Christopher A. Reilly
Bryostatin 1 is a protein kinase C (PKC α, β, δ) activator with anti-inflammatory effects. We hypothesized that bryostatins 1 and 3 could modulate transient receptor potential (TRP) channels via PKC and alter TRP-mediated proinflammatory signaling in lung epithelial cells challenged with a proinflammatory stimulus, coal fly ash (CFA). Bryostatins 1 and 3 inhibited icilin-induced calcium flux in HEK-293 cells overexpressing full-length human transient receptor potential melastatin-8 (TRPM8) but did not inhibit activation by menthol or the activities of human transient receptor potential ankyrin 1, transient receptor potential vanilloid 1 (TRPV1), TRPV3, or TRPV4; mouse and rat TRPM8 were less sensitive to inhibition. TRPM8 inhibition was transient (<24 hours), PKC-dependent, and involved differential phosphorylation of amino acids T17, S27, S850, and S1040. CFA particles stimulate interleukin-8 (IL8) and C-X-C motif chemokine ligand 1 (CXCL1) expression by human bronchial epithelial cells via activation of truncated TRPM8 (TRPM8-Δ801) and TRPV1. However, bryostatins 1 and 3 altered IL8 and CXCL1 mRNA expression with and without CFA treatment. At 4 hours, the bryostatins also suppressed TRPM8 mRNA and induced TRPV1 mRNA, which reversed at 24 hours. These effects were reversed by pharmacological inhibition of PKC isoforms (α, ζ, ε, or η) but not δ, implying a network comprised of presumably PKCα, TRPM8-Δ801, and TRPV1 that regulates IL8 and CXCL1 expression by airway epithelial cells. Finally, an unexpected interaction between TRPV1 and TRPM8, but not TRPM8-Δ801, was also identified. Specifically, the coexpression of TRPM8 and TRPV1 reduced TRPM8 expression and activity, which was reversed by TRPV1 inhibition, revealing novel mechanisms by which bryostatins and PKC affect TRP channel signaling in lung epithelial and potentially other cell types. SIGNIFICANCE STATEMENT: Bryostatins 1 and 3 selectively and transiently inhibit human TRPM8 activity via protein kinase C-dependent phosphorylation and temporally modify the expression and induction of interleukin-8 and C-X-C motif chemokine ligand 1 in lung epithelial cells by regulating TRPV1 and TRPM8 expression. This regulatory nexus may have therapeutic potential for treating airway inflammation.

28 August 2026 in Molecular Pharmacology
Verified
Journal Article
Open access
SSSamantha N. Serna
Samantha N. Serna
ERErin G. Romero
Erin G. Romero
SOShao-En Ong
Shao-En Ong
MGMartin Golkowski
Martin Golkowski
LSLili Sun
Lili Sun
CRChristopher A. Reilly
Christopher A. Reilly
The airway epithelium must constantly adapt to maintain function, as disrupted epithelial homeostasis contributes to asthma and other respiratory diseases. Toxic electrophilic aldehydes, quinones, and substituted phenols are transient receptor potential ankyrin-1 (TRPA1) channel agonists found in common air pollutants, including wood and biomass smoke, cigarette smoke, and vehicle exhaust. TRPA1 agonists damage airway epithelial cells in part by disrupting calcium homeostasis and triggering endoplasmic reticulum stress. A detailed understanding of how inhaled toxicants affect epithelial homeostasis is critical for understanding their effects and managing adverse effects. We integrated results from kinase-targeted phenotypic screening, unbiased mass spectrometry-based global proteomics and phosphoproteomics, live-cell imaging, calcium flux assays, gene expression assays, and Western blot analyses to decipher systematic changes in kinase signaling that control TRPA1 agonist-induced injury. We show that injury coincides with changes in cell structure and motility overlaid with epidermal growth factor receptor (EGFR) transactivation, and that inhibiting kinase pathways known to favor survival and wound repair, including EGFR, extracellular signal-regulated kinase 1/2, phosphoinositide 3-kinase/protein kinase B, and c-Jun N-terminal kinases, exacerbated injury, while inhibiting protein kinase C and p38 mitogen-activated kinase, and others, reduced injury. We attributed the protective effects of protein kinase C and p38 mitogen-activated kinase inhibition to an attenuation of TRPA1 activity, balanced by enhanced transient receptor potential vanilloid-3 expression, resulting in a net shift toward proadaptive kinase-driven signaling downstream of EGFR. Our results support a model in which repair depends on kinase-regulated transitions through a transient injury state that could potentially be targeted prophylactically to reduce injury caused by selected inhaled toxicants. SIGNIFICANCE STATEMENT: This study shows that inhibiting protein kinase C and p38 mitogen-activated kinase reduces transient receptor potential ankyrin-1 activity and enhances transient receptor potential vanilloid-3 expression and prosurvival kinase signaling, favoring cell adaptation and repair following acute injury, offering insight into potential therapeutic approaches to limit transient receptor potential ankyrin-1 agonist-induced injury through a vital network of transient receptor potential channels.